SCHEMBL5545689

SCHEMBL5545689

Cc1ccc(CN[CH]c2ccccc2)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
TNF P01375 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
HBB P68871 1/20 0.39
KMT2A Q03164 1/20 0.39
NFE2L2 Q16236 1/20 0.39
PSMB8 P28062 1/20 0.36
PSMB5 P28074 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541432 0.87 NPC1 (0.49) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL5541813 0.82 KMT2A (0.46) ALDH1A1KDM4EMAPTLMNAHTT
SCHEMBL5542078 0.79 MEN1 (0.37) NPC1ALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL5545644 0.76 ACHE (0.48) ALDH1A1KDM4EMAPTLMNAHTT
SCHEMBL5542584 0.75 SMN1; SMN2 (0.49) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL5545625 0.75 KDM4E (0.50) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL12614430 0.75 KDM4E (0.50) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL20807129 0.75 KDM4E (0.50) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5544369 0.75 GAA (0.41) ALDH1A1KDM4EMAPTHTTMEN1
SCHEMBL5544036 0.74 TACR1 (0.39) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAB9A 2824/4885NPC1 2404/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.